November 5, 2020 -- ABL Europe in France is collaborating with the University Clinic of Tuebingen and Prime Vector Technologies of Germany on a viral vector SARS-CoV-2 vaccine.
In preparation for clinical trials, ABL Europe will develop and manufacture the university's COVID-19 vaccine candidate, which is being developed using a proprietary Orf virus (ORFV). The multivalent vector vaccine will present two different antigens of the SARS-CoV-2 virus and is expected to increase the immune response in immunized individuals.
The collaboration will be funded by the German Federal Ministry for Economic Affairs and Energy and led by the university in close collaboration with the Paul-Ehrlich-Institut in Langen, Germany; it was originally conceptualized in partnership with the University of Applied Sciences Mittelhessen in Giessen, Germany.
The collaborators expect to have chosen a final viral vector by the end of November, and to launch a phase I/II clinical trial in May 2021.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
